Archive · 5 Aug 2025
Pfizer Raises Profit Forecast After Q2 Sales Surge
Pfizer, a big drug company, made more money than expected in the last three months.
Their sales went up to $14.65 billion.
Because they are cutting costs and the dollar is weaker, they think they'll make more money in the future.
They expect to save $7.2 billion by 2027 through these cost-cutting plans.
Sales of their antiviral treatment, Paxlovid, and the COVID vaccine Comirnaty were also much higher than what experts thought they would be.
Pfizer's Q2 sales reached $14.65 billion, exceeding estimates by $1 billion.
The company raised its full-year profit forecast for 2025 due to cost-cutting and a weaker dollar.
Pfizer anticipates $7.2 billion in net savings from cost-saving programs by the end of 2027.
Paxlovid sales reached $427 million, surpassing analysts' expectations of $244.4 million.
Comirnaty sales were $381 million, exceeding the expected $188 million.
- Who
- Pfizer, a pharmaceutical company.
- What
- Pfizer's Q2 sales and profit forecast were announced.
- When
- The announcement was made on Tuesday.
- Where
- New York-based company.
- Why
- The company raised its profit forecast due to cost-cutting and a weaker dollar.
Analysts' Expectations
Pfizer Performance
Sales Projections
Analysts' Expectations
Lower Paxlovid and Comirnaty sales
Pfizer Performance
Higher Paxlovid and Comirnaty sales
- Q2 Sales
- $14.65 billion
- Stock Price Increase
- 2.8%
- 2025 Earnings Forecast
- $2.90 to $3.10 per share
- Net Savings by 2027
- $7.2 billion
- Paxlovid Sales
- $427 million
- Comirnaty Sales
- $381 million